Buy Into the Energy Conundrum

Helix Energy(HLX Quote) spiked well above its 200-day SMA to a high of $41.92 on July 7, but is back below this key level, which is now $37.21. Investors should consider adding to positions on weakness to my annual value level at $27.75.

Hugoton Royalty(HGT Quote) has stayed below its 200-day SMA, now at $32.40. Investors should consider buying weakness to the 50-day SMA at $29.22.

Helmerich & Payne(HP Quote) has been one of the worst performers among the names in my table. It has stayed below its 200-day SMA. If it hadn't done so poorly, I'd say investors should consider adding to positions on weakness to my annual value level at $21.50. But because it has, I'd be less inclined to add shares at this point and instead would sit tight with current share counts.

Oil States(OIS Quote) came within a dime of its 200-day SMA when it was at $35.39 on July 7. I do not have a value level at which to buy, so investors should consider staying with their current positions.

Patterson-UTI(PTEN Quote) has stayed below its 200-day SMA but has been tradable between my annual value level at $24.93 and my semiannual risky level at $29.93.

Rowan(RDC Quote) has also been a poor performer, staying below its 200-day SMA. Investors should be patient with their current holdings. As with Helmerich & Payne, if the stock hadn't done so poorly, investors could consider adding to positions on weakness to my annual value level at $25.34, but given the action, reluctance to do so would be understandable.

RPC(RES Quote) traded above its 200-day SMA (now at $24.15) but is now below it. Investors should consider adding to positions on weakness to my annual value level at $16.42, or on a buy stop above my semiannual pivot at $21.30.